La Clínica Universidad de Navarra inicia en España la administración de donanemab y ha tratado ya a 25 pacientes en fases ...

Treatment is getting better — fast. Here's how we can all benefit.

A panel of experts advising the Food and Drug Administration could on Monday recommend Eli Lilly’s experimental Alzheimer’s drug donanemab for FDA approval, a closely watched decision that could pave ...

On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the data from Eli Lilly And Co’s (NYSE:LLY) Phase 3 Study AACI ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TORONTO -- The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer's disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial ...

The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early Alzheimer’s disease (AD). The agency's Committee for ...

(CNN) — The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease. Donanemab, made by ...

Donanemab has become the second anti-amyloid immunotherapy to win traditional approval from the U.S. Food and Drug Administration. The antibody, which will be marketed as Kisunla, got the official ...

Donanemab—one of the two breakthrough therapies hailed globally for showing promising results in treating Alzheimer's disease—has been approved by India's apex drug regulator, and its maker Eli Lilly ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New research shows that lecanemab and donanemab can slow cognitive decline and extend patients' independence in daily activities. But with high costs and risks, are these treatments truly meaningful ...